

Message from the CEO



Dear Shareholder,

This newsletter gives me an opportunity to welcome our new shareholders and to update our existing shareholders on the progress made over the past nine months.

Our commercial opportunity is neatly summed up by a recent Federal Government policy release highlighting a growing national concern for the economic and social impacts of age-related chronic disease.

https://www.health.gov.au/sites/default/files/2026-03/national-strategic-framework-for-chronic-conditions_0.pdf

As this policy document states, *“chronic conditions account for the majority of the country’s disease burden and are associated with approximately 90% of all deaths. Nearly two in five Australians live with multiple chronic conditions.”*

This is the problem that Filamon is addressing.

All our drug programs are based on novel, first-of-kind mechanisms of action that underpin the Company’s aim of becoming a leader in the development of the next generation treatment of age-related chronic diseases.

We highlight in this newsletter three of our priority programs.

Graham Kelly
CEO and Managing Director

ONCOLOGY



BETA-TT17

A pre-clinical drug candidate. A new class of multi-action, anti-cancer drug with actions of (i) cytotoxicity (cancer cell killing effect), (ii) anti-angiogenesis (blocking formation of cancer-associated blood supply), and (iii) reversal of T cell exhaustion (restoring ability of immune T cells to kill cancer cells).

Rationale is to use BETA-TT17 in combination with immunotherapy (immune checkpoint-inhibiting) drugs across most forms of solid cancer.

Currently undergoing IND-enabling pre-clinical studies to be ready to enter a clinical study in H1-2027.


ADVICE Phase I/II clinical trial

This trial is testing KESONOTIDE™ in patients with late-stage, solid cancers unresponsive to standard treatment. Rationale is to use KESONOTIDE to block a function known as Epithelial-Mesenchymal Transition (EMT) that drives cancer aggression, invasiveness, spread and recurrence.

- Recruitment commenced Dec 2025 at three Sydney sites
- Phase I (dose-escalation from 10, 30, 60, 120mg) has enrolled half its patient target with the drug well tolerated to date

- Phase II (dose-expansion) involving up to 60 patients scheduled to start recruitment in Aug 2026 and involve 10 Australian sites. Full enrolment scheduled by Q3 2027
- Treatment is orally, daily for 18 weeks, with clinical assessment including scans every 6 weeks
- Patients receiving test drug only
- Outcomes are safety, clinical response, biomarkers
- Phase I interim data report anticipated July/Aug 2026.

OPHTHALMOLOGY



BETA-TT8 Eyedropper Gel

Intended as a self-administered eyedropper product to treat inflammatory conditions of the eye including wet age-related macular degeneration (wet AMD), diabetic retinal diseases and uveitis.

- BETA-TT8 confirmed pre-clinically as potent anti-inflammatory drug able to cross the cornea to reach back of eye

- at high drug levels
- BETA-TT8 in both oral and eyedropper forms in standard mouse wet AMD model matched effectiveness of Eylea (market-leading wet AMD treatment) given by injection into the eyeball
- Starting clinical indication is wet AMD, with uveitis scheduled to follow
- An Ophthalmology Advisory Board of

three senior Australian ophthalmologists has been selected and a regulatory affairs advisory company appointed to provide strategic input on the development pathway

- BETA-TT8 Eyedropper Gel currently is being made clinic-ready with the aim of starting a first-in-human clinical study by end of 2026.



Other Pipeline Programs

The three programs above are the priorities. At a lower priority is a pipeline of six other programs across the fields of oncology, chronic fibrotic disease, neurodegenerative diseases, dry AMD and cardiology which are progressing and expected to deliver news flow and add to the overall value of the Company, but whose ongoing progress awaits additional resources from non-dilutive research grants or an IPO.

Intellectual Property



- A range of new patent applications have been lodged to protect drug pipeline intellectual property around novel drug molecules and therapeutic indications
- Progression of existing PCT filings across the ALPHA and BETA platforms into national phase examination. The initial BETA platform patent filing recently had all claims accepted in Japan.

Corporate

Corporate

- WAHL Citadel cornerstone investor commitment letter signed and first tranche of funds received, providing foundational support for our trajectory.
- A WAHL Citadel nominee, Jason Nagy has been appointed to the Board, strengthening governance and strategic direction.
- An initial meeting has been conducted with the ASX to review listing requirements and preparatory processes.

- Current intentions: The pathway to a securities listing (IPO) remains targeted for 2026 contingent on continued data generation, regulatory advancements, funding execution, and market conditions. Raised funds continue to support priority R&D and valuation build.



These steps reflect focused execution. As we near the planned IPO of the company in Q4 of 2026, communications will remain compliant with governance protocols, prioritising material updates.

A prospectus, once registered, will offer full details for investment decisions.

We appreciate your continued confidence in Filamon.